Stock 4598 DELTA-FLY PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Delta-Fly Pharma, Inc.

Equities

4598

JP3549370009

Delayed Japan Exchange
Other stock markets
 02:59:14 16/05/2024 BST 		5-day change 1st Jan Change
565 JPY -20.98% Intraday chart for Delta-Fly Pharma, Inc. -21.42% -44.33%
04-08 Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax CI
03-11 Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
BU
Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax
CI
Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen
BU
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML
CI
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting
BU
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting
CI
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
BU
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323
CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML
CI
Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML
BU
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.
CI
Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 study of DFP-10917 in R/R AML
BU
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917
BU
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited
CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ñ1.300842 billion in funding from Macquarie Group Limited
CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm
CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm
CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa
CI
Delta-Fly Pharma, Inc. : Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927
BU
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4598 Stock
  4. News Delta-Fly Pharma, Inc.